Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 995 across all filing types
Latest filing 2018-08-12 Regulatory Filings
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
First Patient Imaged in Prostate Imaging Study 2 pages 219.7KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the first patients imaged in a prostate imaging study by Telix Pharmaceuticals. It discusses clinical trial progress, partnerships, and market information but does not contain financial data, regulatory filings, or detailed financial reports. It is not an earnings release, annual report, or any form of financial or regulatory filing. It is a corporate announcement related to clinical development and product progress. Therefore, it fits best under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2018-08-12 English
Telix JV Entity Extends Contract with Endocyte to Include EU 1
Regulatory Filings Classification · 95% confidence The document is a short announcement (2678 characters) disclosing an extension of a contract related to a joint venture and clinical trial collaboration. It references compliance with ASX Listing Rule 3.1, indicating it is a regulatory disclosure. There are no financial statements, detailed financial data, or comprehensive report content. The document does not present an annual or interim report, earnings release, or detailed management discussion. It is primarily an update on a contract extension and related business activity. Given the length and content, it fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2018-08-09 English
Telix receives $55m Overseas Finding 2 pages 174.8KB
Capital/Financing Update Classification · 95% confidence The document is an announcement by Telix Pharmaceuticals Limited regarding receiving a $55 million overseas R&D tax finding from Innovation and Science Australia. It details the nature of the funding, its impact on the company, and some background on the company and its operations. There are no financial statements, quarterly or annual results, or detailed financial data presented. The document is relatively short (4742 characters) and serves as a corporate announcement about a financing-related event rather than a full financial report or earnings release. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. The content is about a funding award, which aligns best with Capital/Financing Update (CAP).
2018-08-02 English
TLX and JFE progress Japanese manufacturing partnership 2 pages 168.5KB
Capital/Financing Update Classification · 90% confidence The document is a corporate announcement dated July 26, 2018, describing a definitive commercial manufacturing agreement between Telix Pharmaceuticals and JFE Engineering Corporation. It details progress on manufacturing capabilities and future plans for clinical trials and commercialization. There are no financial statements, regulatory filings, voting results, or management changes. The content is a business update about a partnership and manufacturing progress, not a financial report, earnings release, or regulatory filing. The document length is 4362 characters, which is relatively short and reads as a press release or corporate announcement. Therefore, the best fitting category is Capital/Financing Update (CAP), as it relates to a commercial manufacturing agreement impacting the company's operational capabilities and potential commercialization, which is a form of capital or business update.
2018-07-25 English
Appendix 4C - June 2018 Quarter 7 pages 571.8KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly cashflow statement: June 2018 quarter' and includes detailed consolidated cash flow statements for the quarter and year-to-date periods. It references Appendix 4C, which is a standard quarterly report format required by the Australian Securities Exchange (ASX) under Listing Rule 4.7B. The document contains actual financial data including cash flows from operating, investing, and financing activities, as well as cash balances and estimated cash outflows for the next quarter. It is not merely an announcement or a certification but a substantive quarterly financial report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q2 2018
2018-07-25 English
Quarterly Program Update 9 pages 1.1MB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Program Update' and dated 26th July 2018. It provides detailed updates on clinical trial progress, regulatory filings, manufacturing, and transaction status related to Telix Pharmaceuticals' various cancer treatment programs. The content includes specific clinical trial phases, patient recruitment status, regulatory submission targets, and upcoming milestones. The document is comprehensive and contains substantive operational and clinical data for a quarter, consistent with a quarterly report. It is not a brief announcement, certification, or presentation but a detailed update on the company's quarterly progress. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q2 2018
2018-07-25 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.